• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

First diagnostic test for canine IBD now available

August 14, 2020
dvm360 Staff
dvm360, dvm360 August 2020, Volume 51, Issue 8

Antech’s novel blood test allows veterinarians to rule in or rule out IBD early and with confidence in dogs suffering from associated clinical signs.

Antech Diagnostics (part of Mars Veterinary Health), has announced the availability of its Canine CE-IBD assay, the first blood test for canine inflammatory bowel disease (IBD) (also known as chronic enteropathy, or CE).

Identifying IBD in dogs is traditionally invasive, time-consuming, and costly, but this new blood test allows for a rapid result of “consistent with CE/IBD" or "not consistent with CE/IBD,” according to a company release. It works by incorporating data from three biomarkers—for gliadin sensitivity (similar to gluten sensitivity), bacterial proliferation (Escherichia coli), and intestinal inflammation—to determine possible causes of a dog’s gastrointestinal (GI) signs.

The use of biomarkers, according to a recently published supporting study,1 helps veterinarians determine whether IBD is present, reinforce the need for additional diagnostics, develop more individualized treatment plans, and possibly monitor therapeutic response.

“The opportunity to rule in or rule out IBD early, identify possible causes and use evidence-based medicine to help pet owners understand care recommendations—all quickly and cost-effectively—allow us to treat a dog who is suffering faster,” said Jennifer Ogeer, BSc, DVM, MSc, MBA, MA, vice president of Medical Affairs & Commercial Marketing at Antech, in the release. “We can inspire confidence in a worried pet owner and gain ongoing commitment to our care recommendations, ultimately supporting a dogs rapid return to health.”

Advertisement

The Canine CE-IBD assay can be used when a dog has been experiencing GI signs for a minimum of 3 to 7 days, although results are more accurate when signs persist for at least 3 weeks. The test is currently available to US veterinarians, with availability in Canada following the end of COVID-19–related travel restrictions.

Learn more about this new blood test here.

Reference

1. Estruch, JJ, Barken, D, Bennett, N, et al. Evaluation of novel serological markers and autoantibodies in dogs with inflammatory bowel disease. J Vet Intern Med. 2020;34:1177 1186. doi: 10.1111/jvim.15761

download issueDownload Issue: dvm360 August 2020

Related Content:

MedicalProductsGastroenterologyAssociatesTechniciansdvm360 August 2020
Can our Pride panel answer these LGBTQ+ trivia questions?
Can our Pride panel answer these LGBTQ+ trivia questions?
Creating inclusive spaces for the LGBTQ+ community in vet med
Creating inclusive spaces for the LGBTQ+ community in vet med
Happy Pride Month, Hill's launches Prescription Diet ONC Care, and more
Happy Pride Month, Hill's launches Prescription Diet ONC Care, and more

Advertisement

Latest News

Can our Pride panel answer these LGBTQ+ trivia questions?

Creating inclusive spaces for the LGBTQ+ community in vet med

Happy Pride Month, Hill's launches Prescription Diet ONC Care, and more

CityVet Celina opens in Prosper, Texas

View More Latest News
Advertisement